Low Molecular Weight Fucoidan Suppresses Ferroptosis in Pulmonary Fibrosis

Study Background and Research Question

Pulmonary fibrosis (PF) is a devastating interstitial lung disease characterized by progressive scarring of lung tissue, leading to respiratory failure and premature mortality. Despite a rising global prevalence—projected to reach 1.8 million cases by 2025—current pharmacologic options remain limited, with drugs like pirfenidone and nidanib providing only modest benefits and notable side effects. The urgent need for effective therapies has spurred research into the molecular mechanisms underlying PF, particularly the role of regulated cell death pathways such as ferroptosis. Ferroptosis, distinct from apoptosis, is driven by iron overload and excessive reactive oxygen species (ROS), culminating in lipid peroxidation and cellular dysfunction. Recent evidence has implicated ferroptosis in the pathogenesis of PF, but therapeutic strategies targeting this pathway are still emerging.

Key Innovation from the Reference Study

The reference study by Cao et al. (Algal Research, 2025) provides the first direct evidence that low molecular weight fucoidan (LMWF), a sulfated polysaccharide derived from Laminaria japonica, can inhibit ferroptosis and attenuate pulmonary fibrosis in vivo. While LMWF is known for its antioxidant and immunomodulatory properties, its impact on ferroptotic cell death and mitochondrial function in PF had not been elucidated prior to this investigation. By linking LMWF's action to preservation of mitochondrial membrane potential and suppression of ferroptosis in a clinically relevant model, the study advances mechanistic understanding and therapeutic prospects for fibrotic lung disease.

Methods and Experimental Design Insights

To explore LMWF's therapeutic potential, the researchers established a bleomycin-induced PF mouse model—a well-validated system that recapitulates key features of human disease. Mice received bleomycin to induce fibrosis, followed by treatment with LMWF, with or without the ferroptosis inducer erastin. A suite of complementary methods was employed:

• Histological analyses (hematoxylin and eosin, Masson's trichrome) to assess alveolar structure and collagen deposition
• Immunohistochemistry and ELISA to quantify markers such as alpha-smooth muscle actin, GPX4 (a key ferroptosis regulator), collagen, and TGF-β1
• Flow cytometry for assessment of ROS, apoptosis, and mitochondrial membrane potential in lung tissue
• Non-targeted metabolomics (LC-MS) to delineate metabolic pathways implicated in ferroptosis and PF progression
• Prussian blue staining for iron accumulation

Of particular note is the use of mitochondrial membrane potential assays, a critical readout for both apoptosis and ferroptosis. Fluorescent probes such as JC-1 (5,6-dichloro-2-[(E)-3-(5,6-dichloro-1,3-diethylbenzimidazol-3-ium-2-yl)prop-2-enylidene]-1,3-diethylbenzimidazole iodide) enable sensitive detection of mitochondrial dysfunction, which is central to ferroptotic cell death.

Protocol Parameters

• Bleomycin administration: Intratracheal instillation to induce PF; dose and timing as per standard mouse models.
• LMWF treatment: Administered post-bleomycin; dosing regimen optimized for maximal antifibrotic effect.
• Ferroptosis modulation: Erastin used as a positive control for ferroptosis induction; included to validate the specific effect of LMWF on this pathway.
• Mitochondrial membrane potential assay: Flow cytometry with fluorescent probes (e.g., JC-1) to assess mitochondrial integrity in lung tissue cells.

Core Findings and Why They Matter

LMWF treatment conferred multifaceted benefits in the fibrotic lung model. Key outcomes included:

• Reduction in collagen deposition and improved alveolar architecture, indicating reversal of pathological remodeling.
• Decreased ROS levels and apoptosis in lung tissue, as measured by flow cytometry and biochemical assays.
• Restoration of mitochondrial membrane potential, suggesting protection against mitochondrial dysfunction and cell death.
• Suppression of ferroptosis: Prussian blue staining confirmed reduced iron accumulation, while metabolomics and protein analyses showed reversal of ferroptosis-related metabolic changes and normalization of GPX4 expression.

These results delineate a mechanistic axis whereby LMWF preserves mitochondrial integrity and blocks ferroptosis, thereby attenuating the progression of fibrosis (reference). This provides a rational basis for considering LMWF as a candidate for antifibrotic therapy and highlights the importance of mitochondrial membrane potential as both a biomarker and a therapeutic target in PF.

Comparison with Existing Internal Articles

Recent internal reviews underscore the centrality of mitochondrial membrane potential assays in fibrosis and ferroptosis research. For instance, the article "JC-1 Dye: Precision Mitochondrial Potential Assays in Fibrosis Research" details the application of JC-1 as a robust fluorescent probe for mitochondrial assessment in PF models, aligning closely with the methodology and rationale described by Cao et al. Both sources emphasize the value of ratiometric, sensitive detection of mitochondrial dysfunction in evaluating antifibrotic interventions. Similarly, guidance from "JC-1 (SKU A3516): Scenario-Driven Solutions for Mitochond..." offers practical advice on optimizing mitochondrial membrane potential assays for apoptosis and bioenergetics studies, supporting reproducibility in workflows akin to those used in the reference study. These internal perspectives reinforce the pivotal role of JC-1 and related probes in translational PF research, bridging technical protocols with mechanistic insight.

Limitations and Transferability

While the study by Cao et al. advances the field, several limitations warrant consideration. The use of a single animal model (bleomycin-induced PF) may not capture the full heterogeneity of human disease, and dosing regimens for LMWF require further optimization and safety profiling in preclinical and clinical settings. Additionally, while the mechanistic link between LMWF, mitochondrial function, and ferroptosis is compelling, the precise molecular targets and signaling pathways involved remain to be mapped in detail. Transferability to human PF must be validated in future translational studies, and the long-term effects of LMWF intervention are not yet defined.

Research Support Resources

To facilitate mitochondrial membrane potential assays and apoptosis detection in similar experimental workflows, researchers may utilize JC-1 (SKU A3516), a validated fluorescent probe for assessing mitochondrial health and function. JC-1 enables ratiometric detection of mitochondrial membrane potential changes, crucial for studies of ferroptosis, apoptosis, and cellular bioenergetics. For best results, consult product-specific protocols and maintain rigorous quality control. Workflow recommendations from APExBIO and internal technical articles can further support reproducibility and experimental clarity.